Biotech and pharma companies saw their worst quarter for venture capital since 2019 in Q2 this year, according to a new report from Pitchbook and the National Venture Capital Association.
Biotech and pharma companies saw their worst quarter for venture capital since 2019 in Q2 this year, according to a new report from Pitchbook and the National Venture Capital Association.
